

## **Aerie Pharmaceuticals Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 08-Jul-2013

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drugs..... 9

[Return to Table of Contents](#)

# Aerie Pharmaceuticals Inc

## COMPANY OVERVIEW

Company Name	Aerie Pharmaceuticals Inc
Parent Company Name	Aerie Pharmaceuticals Inc
Website	<a href="http://www.aeriepharma.com/">http://www.aeriepharma.com/</a>
Country	US
Number of Drugs in Active Development	6
Number of Inactive Drugs	1
Number of Patents as Owner	12
Number of Patents as Third Party	1
Number of Deals	0
Key Indications	Glaucoma, Ocular hypertension, Ocular disease, Open angle glaucoma, Dermatological disease, Gastrointestinal disease, Bone disease, Cancer, Obesity, Renal disease
Key Target-based Actions	Rho associated protein kinase inhibitor, Prostanoid receptor agonist, Noradrenaline transporter inhibitor, Rhodopsin kinase inhibitor, Beta-adrenoceptor related kinase-1 inhibitor, Beta-adrenoceptor related kinase-2 inhibitor, CAM kinase inhibitor, GRK5 protein kinase inhibitor, GRK6 protein kinase inhibitor, Protein kinase A inhibitor, Protein kinase C inhibitor, Protein kinase modulator, Protein tyrosine kinase inhibitor
Key Technologies	Small molecule therapeutic, Ophthalmic formulation, Ophthalmic liquid formulation, Ophthalmic drug implant, Solution, Sustained release formulation, Drug combination, Crystalline form, Salt synthesis, Dermatological

## COMPANY PROFILE

### SUMMARY

Aerie Pharmaceuticals Inc, a spin-out of Duke University Medical Center, is a biotechnology company developing therapies for sight-threatening diseases of the eye such as glaucoma. Its discovery platform includes a prodrug technology that increases drug delivery through the cornea.

### EARLY R&D

By November 2007, the company was investigating protein kinase inhibitors and ethacrynic acid derivatives, to lower intraocular pressure in glaucoma patients. At that time, preclinical candidates from the series were anticipated later in that year.

### FINANCIAL

In March 2011, Aerie raised \$30 million through a series B financing.

In October 2005, Aerie raised \$21 million through a series A financing.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Ocular disease	6	1	7

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	4
Discovery	2
No Development Reported	1

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Ocular disease	2	11

### Trials by Phase

Phase	Ongoing	All
Phase 2	2	10
Phase 1	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

[Return to Table of Contents](#)

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

### PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	7	0	7
Endocrine disease	2	0	2
Gastrointestinal disease	8	0	8
Genitourinary disease	8	1	9
Degeneration	2	0	2
Immune disorder	1	0	1
Musculoskeletal disease	8	0	8
Neoplasm	6	0	6
Ocular disease	10	0	10
Neurological disease	1	0	1
Nutritional disorder	4	0	4
Respiratory disease	6	1	7
Inflammatory disease	7	0	7
Gynecology and obstetrics	1	0	1
Dermatological disease	8	0	8

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)





## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### AR-102 (prostaglandin analog, glaucoma), Aerie

<b>Drug Name</b>	AR-102 (prostaglandin analog, glaucoma), Aerie
<b>Key Synonyms</b>	
<b>Originator Company</b>	Aerie Pharmaceuticals Inc
<b>Active Companies</b>	Aerie Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Glaucoma
<b>Target-based Actions</b>	Prostanoid receptor agonist
<b>Other Actions</b>	Ophthalmological agent
<b>Technologies</b>	Ophthalmic formulation, Ophthalmic liquid formulation, Small molecule therapeutic
<b>Last Change Date</b>	19-Aug-2011

### AR-12286

<b>Drug Name</b>	AR-12286
<b>Key Synonyms</b>	
<b>Originator Company</b>	Aerie Pharmaceuticals Inc
<b>Active Companies</b>	Aerie Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Open angle glaucoma, Ocular hypertension, Glaucoma
<b>Target-based Actions</b>	Rho associated protein kinase inhibitor
<b>Other Actions</b>	Antiglaucoma agent, Antihypertensive, Ophthalmological agent
<b>Technologies</b>	Ophthalmic formulation, Ophthalmic liquid formulation, Solution, Small molecule therapeutic
<b>Last Change Date</b>	27-May-2013

[Return to Table of Contents](#)



**AR-13324**

<b>Drug Name</b>	AR-13324
<b>Key Synonyms</b>	
<b>Originator Company</b>	Aerie Pharmaceuticals Inc
<b>Active Companies</b>	Aerie Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Ocular hypertension, Glaucoma
<b>Target-based Actions</b>	Noradrenaline transporter inhibitor, Rho associated protein kinase inhibitor
<b>Other Actions</b>	Antihypertensive, Antiglaucoma agent
<b>Technologies</b>	Ophthalmic formulation, Solution, Small molecule therapeutic
<b>Last Change Date</b>	30-May-2013

**AR-12286 + travoprost (fixed dose combination, ocular hypertension/glaucoma), Aerie**

<b>Drug Name</b>	AR-12286 + travoprost (fixed dose combination, ocular hypertension/glaucoma), Aerie
<b>Key Synonyms</b>	
<b>Originator Company</b>	Aerie Pharmaceuticals Inc
<b>Active Companies</b>	Aerie Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Open angle glaucoma, Ocular hypertension
<b>Target-based Actions</b>	Prostanoid receptor agonist, Rho associated protein kinase inhibitor
<b>Other Actions</b>	Ophthalmological agent, Topical antiglaucoma agent, PGF2 alpha agonist
<b>Technologies</b>	Drug combination, Ophthalmic formulation, Ophthalmic liquid formulation, Small molecule therapeutic
<b>Last Change Date</b>	30-May-2013

[Return to Table of Contents](#)


### latanoprost (sustained release ocular implant), Aerie

<b>Drug Name</b>	latanoprost (sustained release ocular implant), Aerie
<b>Key Synonyms</b>	latanoprost
<b>Originator Company</b>	Aerie Pharmaceuticals Inc
<b>Active Companies</b>	Aerie Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Ocular disease
<b>Target-based Actions</b>	
<b>Other Actions</b>	PGF2 alpha agonist, Ophthalmological agent
<b>Technologies</b>	Sustained release formulation, Ophthalmic formulation, Ophthalmic drug implant, Small molecule therapeutic
<b>Last Change Date</b>	17-Oct-2011

### AR-12286 (ophthalmic drug implant/sustained release formulation, ocular diseases), Aerie

<b>Drug Name</b>	AR-12286 (ophthalmic drug implant/sustained release formulation, ocular diseases), Aerie
<b>Key Synonyms</b>	
<b>Originator Company</b>	Aerie Pharmaceuticals Inc
<b>Active Companies</b>	Aerie Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Ocular disease
<b>Target-based Actions</b>	Rho associated protein kinase inhibitor
<b>Other Actions</b>	Ophthalmological agent
<b>Technologies</b>	Sustained release formulation, Ophthalmic formulation, Ophthalmic drug implant, Small molecule therapeutic
<b>Last Change Date</b>	14-Oct-2011

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

